Clinical trials: Class IV Angina
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
- Conditions
- Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
- Trial name
- NCT05938725
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Kyverna Therapeutics
Heart Failure
Optimal Balance Alfapump® System Feasibility Study
1. Summary of Clinical Investigation A summary of the clinical investigation is provided below and includes the primary objective of the study, the safety and feasibility endpoints, the number of subjects to be enrolled, the…
- Trial name
- OPTIMALBALANCE (NCT03032211)
- Testing
- Alfapump
- Where
- Hungary
- Sponsor
- Sequana Medical N.V.